AL-8810

AL-8810 is a potent and selective antagonist of the PGF 2α receptor (FP receptor) . AL-8810 is an activator of MAPK and ERK1/2. The Ki of the FP receptor of mouse 3T3 cells and rat A7r5 cells are 0.2±0.06 μM and 0.4±0.1 μM, respectively. AL-8810 can be used in the study of elevated intraocular pressure (OHT) and primary open-angle glaucoma (POAG) [1][2][3][4][5].

Product Specifications

CAS Number

[246246-19-5]

UNSPSC

12352005

Target

ERK; p38 MAPK; Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway; Stem Cell/Wnt

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/al-8810.html

Purity

99.00

Solubility

10 mM in DMSO|DMSO : ≥ 10mg/mL

Smiles

O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](C2CC3=C(C=CC=C3)C2)O)[C@@H](F)C[C@@H]1O

Molecular Formula

C24H31FO4

Molecular Weight

402.50

References & Citations

[1]Griffin BW, et al. AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor. J Pharmacol Exp Ther. 1999 Sep;290 (3) :1278-84.|[2]Kim YT, et al. Prostaglandin FP receptor inhibitor reduces ischemic brain damage and neurotoxicity. Neurobiol Dis. 2012 Oct;48 (1) :58-65. doi: 10.1016/j.nbd.2012.06.003. Epub 2012 Jun 16.|[3]Goupil E, et al. Biasing the prostaglandin F2α receptor responses toward EGFR-dependent transactivation of MAPK. Mol Endocrinol. 2012 Jul;26 (7) :1189-202.|[4]Sharif NA, et al. Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility. Br J Pharmacol. 2019 Apr;176 (8) :1059-1078.|[5]Glushakov AV, et al. Prostaglandin F2α FP receptor antagonist improves outcomes after experimental traumatic brain injury. J Neuroinflammation. 2013 Oct 30;10:132.